SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1235AstraZeneca Deal A Positive ¦ Conclusion: We note that this deal has betterdr.praveen-2/12/2007
1234Message 23253093 Cool...we have more money to spend now:-)dr.praveen-2/5/2007
1233First Results Reported for an AMD Eye Drop: investorshub.comDewDiligence_on_SI-1/31/2007
1232I do not know the difference. My point is that Erbitux is humanized, and have hiMiljenko Zuanic-1/27/2007
1231"I continue to think that Erbitux is better than Vectibix due to local immufdu1983-1/27/2007
1230Thanks Miljenko..very much..the work continues.. Here's a full-length preclzeta1961-1/26/2007
1229Genentech Warns Doctors Of Stroke Risk With Lucentis By MARILYN CHASE January 26dr.praveen-1/26/2007
1228Hi Elizabeth, My view is that single receptor blockage (if there is no internalMiljenko Zuanic-1/26/2007
1227Miljenko, have you been keeping in touch with IMCL's anti-VEGFR2 drug?..Aftezeta1961-1/26/2007
1226Today Merrill estimates that chronic dosing is looking like Q3months..whooda thuzeta1961-1/26/2007
1225I am positive that CRP will be reduced, and they may hit secondary end-point as Miljenko Zuanic-1/19/2007
1224What do you think about the chances?Thxdr.praveen-1/19/2007
1223IL-1 Trap (Rilonacept) in CAD, exploratory PII trial: clinicaltrials.govMiljenko Zuanic-1/18/2007
1222Few clarifications on AMD PII (from JPM): four doses (0.5 to 4 mg) and two sheduMiljenko Zuanic-1/12/2007
1221duplicateMiljenko Zuanic-1/10/2007
1220<<But, they did not quote survival results as secondary end-point, so resuMiljenko Zuanic-1/10/2007
1219Elizabeth, HR or <0.5 (with no overlapping intervals) is very good. AnythingMiljenko Zuanic-1/10/2007
1218Sorafenib in same NEJM issue Volume 356:125-134 January 11, 2007 Number 2 Nzeta1961-1/10/2007
1217Miljenko, Sutent in 1st line metastatic RCC 11 month PFS versus 5month for IFN..zeta1961-1/10/2007
1216Off label dosing regimen not good for lucentis but may set a higher real life barkrw-1/9/2007
1215Alternative protein mfg, hcv and biogenerics. Three fertile and exciting areas.rkrw-1/8/2007
1214Miljenko, Thanks for the note. After reviewing this and past information I thiPseudo Biologist-1/8/2007
1213Mike thanks for pointing that out. I had forgotten about Member Profiles. Dew&keokalani'nui-1/7/2007
1212Fine point taken. On the recommendation question I have no idea. I don't urkrw-1/6/2007
1211It is a free country. If you're curious about Dew's picks, I see that hMike McFarland-1/6/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News